Oral furosemide and hydrochlorothiazide/amiloride versus intravenous furosemide for the treatment of nephrotic edema

Not Applicable

Completed

• Conditions: Diuretic treatment in nephrotic syndrome and diuretic-resistant edema; Urological and Genital Diseases; Nephrotic syndrome

• Registration Number: ISRCTN28785798
• Lead Sponsor: Institutul Clinic Fundeni

Brief Summary

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37959360/ (added 07/12/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-29
• Study Completion: 2023-05-01
• Last Update Posted: 19 December 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

1. Age >18 years old
2. Nephrotic syndrome in patients without diabetes mellitus
3. Diuretic resistance
4. eGFR >30 ml/min/1.73 m²

Exclusion Criteria

1. Age <18 years old
2. Nephrotic syndrome in patients with type 1 or type 2 diabetes
3. eGFR <30 ml/min/1.73 m²
4. Hypokalemia and hyperkalemia
5. Severe hyponatremia
6. Alcalosis
7. Severe pulmonary congestion
8. Active infection
9. NSAIDs use within the last month
10. Pregnancy
11. Kidney transplant
12. Known allergy to furosemide, hydrochlorothiazide or amiloride
13. Patients with a defibrillator/pacemaker/metal prosthesis

Study & Design

• Study Type: Interventional
• Study Design: Not specified